insulin vs glp-1 Agonists: Increasing Effective Release Schematic of action of GLP-1

( c-e ) Immunoblot of the indicated proteins in cells treated with the IDH1 inhibitor ( c ), cultured under glutamine starvation (GS) ( d ), or supplemented with succinate ( e ) and supplemented with KG, propionylcarnitine (Prop-Carn), or butyrylcarnitine (But-Carn)

Exp Cell Res (1986) 162:50720

Resume your regular schedule the following week

One of the first important studies was carried out in Norway more than a decade ago by Eha Nurk and Helga Refsum and colleagues in Norway

Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols

This means food stays in your stomach for a longer time, contributing to prolonged fullness and a more gradual release of nutrients into your bloodstream